Controlled trial of phetharbital, a non-hypnotic barbiturate, in unconugated hyperbilirubinaemia.

Eleven patients with mild unconjugated hyperbilirubinaemia (Gilbert's syndrome) took part in a double-blind cross-over trial of phenobarbitone and phetharbital, a non-hypnotic barbiturate. Significant reductions in plasma bilirubin were observed with both drugs, but six patients complained of sleepiness on phenobarbitone, and phetharbital was preferred by most patients. Phetharbital was also effective in the rare severe unconjugated hyperbilirubinaemia of the Crigler-Najjar syndrome (Type 2). Symptoms attributed to Gilbert's syndrome, including nausea and abdominal pain, were less consistently relieved.
AuthorsJ Hunter, R P Thompson, M O Rake, R Williams
JournalBritish medical journal (Br Med J) Vol. 2 Issue 5760 Pg. 497-9 (May 29 1971) ISSN: 0007-1447 [Print] ENGLAND
PMID4931488 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Barbiturates
  • Bilirubin
  • Phenobarbital
  • Abdomen
  • Barbiturates (therapeutic use)
  • Bilirubin (blood)
  • Clinical Trials as Topic
  • Female
  • Humans
  • Hyperbilirubinemia, Hereditary (drug therapy)
  • Male
  • Nausea (complications, drug therapy)
  • Pain (drug therapy)
  • Phenobarbital (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: